Receipt of R&D Milestone Payment from ODS025 Technology Transfer Agreement (Min. ~4.73B KRW)

Company expects to receive R&D milestone payment under ODS025 technology transfer agreement with Boehringer Ingelheim International GmbH (Germany)
Payment amount undisclosed but represents at least 10% of 2025 consolidated revenue of approximately 47.3 billion KRW (≥ 4.73 billion KRW)
Invoice date: 2026-05-06; payment expected within 45 days of invoice receipt
Agreement signed on October 15, 2025 prior to listing; may be terminated if clinical trials or regulatory approvals fail
Revenue recognition depends on successful development and regulatory approval

Filing: Major Management Matters Related to Investment Judgment (Receipt of R&D Expenses Related to ODS025 Technology Transfer Agreement)
Company: Aimed Bio (0009K0)
Submission: Aimed Bio Inc.
Receipt: 05-06-2026
Under KRX KOSDAQ Market Division